EGFR inhibitors
Blueprint Medicines Acquires Lengo Therapeutics in $465M Deal
The acquisition adds Lengo's EGFR inhibitor LNG-451 to Blueprint's pipeline, which already includes two other investigational EGFR inhibitors.
Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations
The trial will evaluate Orpathys plus Tagrisso in patients with advanced or metastatic EGFR-positive, MET-amplified NSCLC who have progressed after EGFR inhibitor therapy.
Geneseeq Multi-Biomarker Approach Predicts EGFR-Mutated NSCLC Patients' Adjuvant Therapy Benefit
Premium
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.
Blueprint Medicines, Zai Lab Ink $615M Licensing Agreement for EGFR Inhibitors
Zai Lab will have exclusive rights to commercialize Blueprint's BLU-945 and BLU-701 in EGFR-mutated NSCLC in greater China.
SpringWorks Therapeutics Licenses EGFR Inhibitors From Dana-Farber, Inks Two R&D Partnerships
The firm has entered collaborations with both Stanford Medicine and Ab Magnitude to further develop the new portfolio of lung cancer therapeutics.
Sep 19, 2020